Loading...
XNAS
LXRX
Market cap994mUSD
Jul 09, Last price  
2.25USD
1D
-0.88%
1Q
30.81%
Jan 2017
-83.73%
IPO
-98.12%
Name

Lexicon Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:LXRX chart
P/E
—
P/S
20.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.78%
Rev. gr., 5y
15.72%
Revenues
50m
+60.24%
72,798,00050,118,00032,321,00010,700,0004,908,0001,849,0001,089,0002,222,00022,854,000130,014,00083,337,00090,335,00063,209,000322,073,00023,995,000298,000139,0001,204,00031,081,00049,803,000
Net income
-50m
L-74.88%
-54,311,000-58,794,000-76,860,000-82,780,000-101,775,000-116,215,000-110,211,000-104,126,000-100,294,000-4,682,000-141,429,000-129,050,000-120,548,000130,133,000-58,574,000-87,758,000-101,944,000-177,119,000-200,403,000-50,341,000
CFO
-68m
L-62.05%
-56,909,000-74,323,000-95,600,000-89,016,000-82,368,000-87,938,000-94,460,000-91,079,000-75,622,000184,776,000-175,628,000-185,394,000-148,607,000113,807,000-142,969,000-87,017,000-88,851,000-161,897,000-178,780,000-67,851,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
URL
https://www.lexpharma.com/
IPO date
Apr 07, 2000
Employees
135
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT